Valuation: Royalty Pharma plc

Market Cap 25.01B 21.88B 20.18B 18.64B 35.37B 2,386B 35.96B 241B 94.69B 1,175B 93.92B 91.88B 4,040B P/E 2026 *
21.3x
P/E 2027 * 14.9x
Enterprise Value 34.17B 29.89B 27.57B 25.46B 48.31B 3,259B 49.12B 329B 129B 1,605B 128B 125B 5,519B EV / Sales 2026 *
9.95x
EV / Sales 2027 * 9.37x
Free-Float
71.97%
Yield 2026 *
1.77%
Yield 2027 * 1.85%
1 day-2.64%
1 week-2.32%
Current month+0.64%
1 month+2.06%
3 months+17.81%
6 months+40.48%
Current year+46.04%
1 week 55.96
Extreme 55.96
58.84
1 month 51.15
Extreme 51.15
58.84
Current year 38.29
Extreme 38.29
58.84
1 year 34.08
Extreme 34.0805
58.84
3 years 24.05
Extreme 24.05
58.84
5 years 24.05
Extreme 24.05
58.84
10 years 24.05
Extreme 24.05
58.84
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

Executive/Senior Manager

-9,099 0.0021%
06-29Sell

Executive/Senior Manager

-130,000 0.0293%
06-29Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-2.64%-2.32%+57.45%+83.75% 25.01B
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -1.32%-3.15%+29.80%+59.41% 359.89B
Weighted average by Cap. -1.32%-2.95%+36.89%+83.91%

Financials

2026 *2027 *
Net sales 3.43B 3B 2.77B 2.56B 4.86B 328B 4.94B 33.1B 13B 161B 12.89B 12.61B 555B 3.66B 3.21B 2.96B 2.73B 5.18B 349B 5.27B 35.32B 13.87B 172B 13.76B 13.46B 592B
Net income 1.65B 1.45B 1.33B 1.23B 2.34B 158B 2.38B 15.94B 6.26B 77.71B 6.21B 6.07B 267B 2.24B 1.96B 1.8B 1.67B 3.16B 213B 3.22B 21.56B 8.47B 105B 8.4B 8.22B 361B
Net Debt 9.15B 8.01B 7.39B 6.82B 12.94B 873B 13.16B 88.24B 34.65B 430B 34.37B 33.62B 1,478B 9.33B 8.16B 7.52B 6.95B 13.18B 889B 13.41B 89.89B 35.3B 438B 35.01B 34.25B 1,506B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-10 US$56.43 -2.64% 2,518,730
26-07-09 US$57.96 -0.70% 3,322,552
26-07-08 US$58.37 +0.99% 3,281,287
26-07-07 US$57.80 +1.55% 2,611,210
26-07-06 US$56.92 -1.47% 3,105,914
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
56.43USD
Average target price
59.25USD
Spread / Average Target
+5.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock